Development of 2A peptide-based strategies in the design of multicistronic vectors

Expert Opinion on Biological Therapy

Volumn 5, Issue 5, 2005, Pages 627-638

  Szymczak, Andrea L ^b   Vignali, Dario A A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

2A peptide; Gene therapy; IRES; Vectors

Indexed keywords

GENE PRODUCT; PEPTIDE 2A DERIVATIVE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL TISSUE; BIOTECHNOLOGY; CELL TYPE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG DESIGN; GENE EXPRESSION REGULATION; GENE THERAPY; MOUSE; MULTICISTRONIC VECTOR; NONHUMAN; PEPTIDE ANALYSIS; PEPTIDE MAPPING; PROTEIN LOCALIZATION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; VIRAL GENE DELIVERY SYSTEM;

AMINO ACID SEQUENCE; ANIMALS; GENETIC VECTORS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; TECHNOLOGY, PHARMACEUTICAL;

EID: 20344377636     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.5.627     Document Type: Review

References (102)

1. SZYMCZAK AL, WORKMAN CJ, WANG Y et al.: Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat. Biotechnol. (2004) 22:589-594. A detailed in vitro and in vivo analysis of the use of multiple, different 2A peptide sequences in a single vector to reconstitute deficiency of four genes.
2. BOUAYADI K, HOFFMANN JS, FONS P, TIRABY M, REYNES JP, CAZAUX C: Overexpression of DNA polymerase beta sensitizes mammalian cells to 2′,3′-deoxycytidine and 3′-azido-3′-deoxythymidine. Cancer Res. (1997) 57:110-116.
3. ROGULSKI KR, KIM JH, KIM SH, FREYTAG SO: Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther. (1997) 8:73-85.
4. KESSELS HW, WOLKERS MC, VAN DEN BOOM MD, VAN DER VALK MA, SCHUMACHER TN: Immunotherapy through TCR gene transfer. Nat. Immunol. (2001) 2:957-961.
5. CHAPLIN PJ, CAMON EB, VILLARREAL-RAMOS B, FLINT M, RYAN MD, COLLINS RA: Production of interleukin-12 as a self-processing 2A polypeptide. J. Interferon Cytokine Res. (1999) 19:235-241.
6. ZITVOGEL L, TAHARA H, CAI Q et al.: Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum. Gene Ther. (1994) 5:1493-1506.
7. TAHARA H, ZITVOGEL L, STORKUS WJ et al.: Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. (1995) 154:6466-6474.
8. CHEN SH, KOSAI K, XU B et al.: Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. (1996) 56:3758-3762.
9. TAHARA H, LOTZE MT: Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther. (1995) 2:96-106.
10. WALTHER W, STEIN U: Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs (2000) 60:249-271.
11. KAY MA, GLORIOSO JC, NALDINI L: Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. (2001) 7:33-40.
12. KRISKY DM, MARCONI PC, OLIGINO TJ et al.: Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther. (1998) 5:1517-1530.
13. WANG X, ZHANG GR, SUN M, GELLER AI: General strategy for constructing large HSV-1 plasmid vectors that coexpress multiple genes. Biotechniques (2001) 31:204-210, 212.
14. DE FELIPE P: Polycistronic viral vectors. Curr. Gene Ther. (2002) 2:355-378. An excellent review describing different strategies of multigene expression.
15. FUSSENEGGER M: The impact of mammalian gene regulation concepts on functional genomic research, metabolic engineering, and advanced gene therapies. Biotechnol. Prog. (2001) 17:1-51.
16. WALTHER W, STEIN U: Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting. J. Mol. Med. (1996) 74:379-392.
17. DACHS GU, DOUGHERTY GJ, STRATFORD IJ, CHAPLIN DJ: Targeting gene therapy to cancer: a review. Oncol. Res. (1997) 9:313-325.
18. HARRINGTON KJ, LINARDAKIS E, VILE RG: Transcriptional control: an essential component of cancer gene therapy strategies? Adv. Drug Deliv. Rev. (2000) 44:167-184.
19. EMERMAN M, TEMIN HM: Comparison of ptomoter suppression in avian and murine retrovirus vectors. Nucleic Acids Res. (1986) 14:9381-9396.
20. BANDYOPADHYAY PK, TEMIN HM: Expression of complete chicken thymidine kinase gene inserted in a retrovirus vector. Mol. Cell. Biol. (1984) 4:749-754.
21. NAKAJIMA K, IKENAKA K, NAKAHIRA K, MORITA N, MIKOSHIBA K: An improved retroviral vector for assaying promoter activity. Analysis of promoter interference in pIP211 vector. FEBS Lett. (1993) 315:129-133.
22. PALMER TD, HOCK RA, OSBORNE WR, MILLER AD: Efficient retrovirus-mediated transfer and expression of a human adenosine deaminase gene in diploid skin fibroblasts from an adenosine deaminase-deficient human. Proc. Natl. Acad. Sci. USA (1987) 84:1055-1059.
23. CULLEN BR, LOMEDICO PT, JU G: Transcriptional interference in avian retroviruses-implications for the promoter insertion model of leukaemogenesis. Nature (1984) 307:241-245.
24. BOERKOEL CF, KUNG HJ: Transcriptional interaction between retroviral long terminal repeats (LTRs): mechanism of 5′ LTR suppression and 3′ LTR promoter activation of c-myc in avian B-cell lymphomas. J. Virol. (1992) 66:4814-4823.
25. GAMA SOSA MA, ROSAS DH, DEGASPERI R, MORITA E, HUTCHISON MR, RUPRECHT RM: Negative regulation of the 5′ long terminal repeat (LTR) by the 3′ LTR in the murine proviral genome. J. Virol. (1994) 68:2662-2670.
26. XU L, YEE JK, WOLFF JA, FRIEDMANN T: Factors affecting long-term stability of Moloney murine leukemia virus-based vectors. Virology (1989) 171:331-341.
27. MCLACHLIN JR, MITTEREDER N, DAUCHER MB, KADAN M, EGLITIS MA: Factors affecting retroviral vector function and structural integrity. Virology (1993) 195:1-5.
28. STOLTZFUS CM, LORENZEN SK, BERBERICH SL: Noncoding region between the env and src genes of Rous sarcoma virus influences splicing efficiency at the src gene 3′ splice site. J. Virol. (1987) 61:177-184.
29. STOLTZFUS CM, FOGARTY SJ: Multiple regions in the Rous sarcoma virus src gene intron act in cis to affect the accumulation of unspliced RNA. J. Virol. (1989) 63:1669-1676.
30. ARRIGO S, YUN M, BEEMON K: cis-acting regulatory elements within gag genes of avian retroviruses. Mol. Cell. Biol. (1987) 7:388-397.
31. DOUGHERTY JP, TEMIN HM: High mutation rate of a spleen necrosis virus-based retrovirus vector. Mol. Cell. Biol. (1986) 6:4387-4395.
32. MILLER CK, TEMIN HM: Insertion of several different DNAs in reticuloendotheliosis virus strain T suppresses transformation by reducing the amount of subgenomic mRNA. J. Virol. (1986) 5875-80.
33. KARREMAN C: A new set of positive/negative selectable markers for mammalian cells. Gene (1998) 218:57-61.
34. THOMAS CL, MAULE AJ: Limitations on the use of fused green fluorescent protein to investigate structure-function relationships for the cauliflower mosaic virus movement protein. J Gen. Virol. (2000) 81:1851-1855.
35. GAKEN J, JIANG J, DANIEL K et al.: Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron. Gene Ther. (2000) 7:1979-1985.
36. VAGNER S, GALY B, PYRONNET S: Irresistible IRES. Attracting the translation machinery to internal ribosome entry sites. EMBO Rep. (2001) 2:893-898.
37. JACKSON RJ: RNA translation. Picornaviruses break the rules. Nature (1988) 334:292-293.
38. PELLETIER J, SONENBERG N: Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature (1988) 334:320-325.
39. JANG SK, KRAUSSLICH HG, NICKLIN MJ, DUKE GM, PALMENBERG AC, WIMMER E: A segment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J. Virol. (1988) 62:2636-2643.
40. MORGAN RA, COUTURE L, ELROY-STEIN O, RAGHEB J, MOSS B, ANDERSON WF: Retroviral vectors containing purative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res. (1992) 20:1293-1299.
41. HELLEN CU, SARNOW P: Internal ribosome entry sites in eukaryotic mRNA molecules. Genes Dev. (2001) 15:1593-1612.
42. BERLIOZ C, TORRENT C, DARLIX JL: An internal ribosomal entry signal in the rat VL30 region of the Harvey murine sarcoma virus leader and its use in dicistronic retroviral vectors. J. Virol. (1995) 69:6400-6407.
43. LOPEZ-LASTRA M, GABUS C, DARLIX JL: Characterization of an internal ribosomal entry segment within the 5′ leader of avian reticuloendotheliosis virus type A RNA and development of novel MLV-REV-based retroviral vectors. Hum. Gene Ther. (1997) 8:1855-1865.
44. WOOLAWAY KE, LAZARIDIS K, BELSHAM GJ, CARTER MJ, ROBERTS LO: The 5′ untranslated region of Rhopalosiphum padi virus contains an internal ribosome entry site which functions efficiently in mammalian, plant, and insect translation systems. J. Virol. (2001) 75:10244-10249.
45. DOROKHOV YL, SKULACHEV MV, IVANOV PA et al.: Polypurine (A)-rich sequences promote cross-kingdom conservation of internal ribosome entry. Proc. Natl. Acad. Sci. USA (2002) 99:5301-5306.
46. MACEJAK DG, SARNOW P: Translational regulation of the immunoglobulin heavy-chain binding protein mRNA. Enzyme (1990) 44:310-319.
47. GHATTAS IR, SANES JR, MAJORS JE: The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol. Cell. Biol. (1991) 11:5848-5859.
48. SUGIMOTO Y, HRYCYNA CA, AKSENTIJEVICH II, PASTAN II, GOTTESMAN MM: Coexpression of a multldrug-resistance gene (MDR1) and herpes simplex virus thymidine kinase gene as part of a bicistronic messenger RNA in a retrovirus vector allows selective killing of MDR 1-transduced cells. Clin. Cancer Res. (1995) 1:447-457.
49. SUGIMOTO Y, AKSENTIJEVICH I, MURRAY GJ, BRADY RO, PASTAN I, GOTTESMAN MM: Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease. Hum. Gene Ther. (1995) 6:905-915.
50. VEELKEN H, RE D, KULMBURG P et al.: Systematic evaluation of chimeric marker genes on dicistronic transcription units for regulated expression of rransgenes in vitro and in vivo. Hum. Gene Ther. (1996) 7:1827-1836.
51. GALLARDO HF, TAN C, SADELAIN M: The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of rwo transgenes in human primary T lymphocytes. Gene Ther. (1997) 4:1115-1119.
52. SALEH M: A retroviral vector that allows efficient coexpression of two genes and the versatility of alternate selection markers. Hum. Gene Ther. (1997) 8:979-983.
53. LEVENSON W, TRANSUE ED, RONINSON IB: Internal ribosomal entry site-containing retroviral vectors with green fluorescent protein and drug resistance markers. Hum. Gene Ther. (1998) 9:1233-1236.
54. OVERELL RW, WEISSER KE, COSMAN D: Stably transmitted triple-promoter retroviral vectors and their use in transformation of primary mammalian cells. Mol. Cell. Biol (1988) 8:1803-1808.
55. PAULUS W, BAUR I, BOYCE FM, BREAKEFIELD XO, REEVES SA: Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J. Virol. (1996) 70:62-67.
56. LIU X, CONSTANTINESCU SN, SUN Y et al.: Generation of mammalian cells stably expressing multiple genes at predetermined levels. Anal. Biochem. (2000) 280:20-28.
57. DOUIN V, BORNES S, CREANCIER L et al.: Use and comparison of different internal ribosomal entry sites (IRES) in tricistronic retroviral vectors. BMC Biotechnol. (2004) 4:16.
58. JANG SK, DAVIES MV, KAUFMAN RJ, WIMMER E: Initiation of protein synthesis by internal entry of ribosomes into the 5′ nontranslated region of encephalomyocarditis virus RNA in vivo. J. Virol. (1989)63:1651-1660.
59. KOZAK M: Alternative ways to think about mRNA sequences and proteins that appear to promote internal initiation of translation. Gene (2003) 318:1-23.
60. BORMAN AM, BAILLY JL, GIRARD M, KEAN KM: Picornavirus internal ribosome entry segments: comparison of translation efficiency and the requirements for optimal internal initiation of translation in vitro. Nucleic Acids Res. (1995) 23:3656-3663.
61. BORMAN AM, LE MP, GIRARD M, KEAN KM: Comparison of picornaviral IRES-driven internal initiation of translation in cultured cells of different origins. Nucleic Acids Res. (1997) 25:925-932.
62. ROBERTS LO, SEAMONS RA, BELSHAM GJ: Recognition of picornavirus internal ribosome entry sites within cells; influence of cellular and viral proteins. RNA (1998) 4:520-529.
63. MIZUGUCHI H, XU Z, ISHII-WATABE A, UCHIDA E, HAYAKAWA T: IRES-dependent second gene expression is significantly lower than cap- dependent first gene expression in a bicistronic vector. Mol. Ther. (2000) 1:376-382.
64. KAUFMAN RJ, DAVIES MV, WASLEY LC, MICHNICK D: Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus. Nucleic Acids Res. (1991) 19:4485-4490.
65. DIRKS W, WIRTH M, HAUSER H: Dicistronic transcription units for gene expression in mammalian cells. Gene (1993) 128:247-249.
66. ZHU J, MUSCO ML, GRACE MJ: Three-color flow cytometry analysis of tricistronic expression of eBFP, eGFP, and eYFP using EMCV-IRES linkages. Cytometry (1999) 37:51-59.
67. FLASSHOVE M, BARDENHEUER W, SCHNEIDER A et al.: Type and position of promoter elements in retroviral vectors have substantial effects on the expression level of an enhanced green fluorescent protein reporter gene. J. Cancer Res. Clin. Oncol. (2000) 126:391-399.
68. PAQUIN A, JAALOUK DE, GALIPEAU J: Retrovector encoding a green fluorescent protein-herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications. Hum. Gene Ther. (2001) 12:13-23.
69. HENNECKE M, KWISSA M, METZGER K et al.: Composition and arrangement of genes define the strength of IRES-driven translation in bicistronic mRNAs. Nucleic Acids Res. (2001) 29:3327-3334.
70. ROBERTS LO, SEAMONS RA, BELSHAM GJ: Recognition of picornavirus internal ribosome entry sites within cells; influence of cellular and viral proteins. RNA (1998) 4:520-529.
71. SHAW-JACKSON C, MICHIEL ST: Absence of internal ribosome entry site-mediated tissue specificity in the translation of a bicistronic transgene. J. Virol. (1999) 73:2729-2738.
72. HARRIES M, PHILLIPPS N, ANDERSON R, PRENTICE G, COLLINS M: Comparison of bicistronic retroviral vectors containing internal ribosome entry sites (IRES) using expression of human interleukin-12 (IL-12) as a readout. J. Gene Med. (2000) 2:243-249.
73. REYNOLDS JE, KAMINSKI A, KETTINEN HJ et al.: Unique features of internal initiation of hepatitis C virus RNA translation. EMBO J. (1995) 14:6010-6020.
74. NANBRU C, PRATS AC, DROOGMANS L, DEFRANCE P, HUEZ G, KRUYS V: Translation of the human c-myc p0 tricistronic mRNA involves two independent internal ribosome entry sites. Oncogene (2001) 20:4270-4280.
75. CHAPPELL SA, EDELMAN GM, MAURO VP: A 9-nt segment of a cellular mRNA can function as an internal ribosome entry site (IRES) and when present in linked multiple copies greatly enhances IRES activity. Proc. Natl. Acad. Sci. USA (2000) 97:1536-1541.
76. REISER J, LAI Z, ZHANG XY, BRADY RO: Development of multigene and regulated lentivirus vectors. J. Virol. (2000) 74:10589-10599
77. OWENS GC, CHAPPELL SA, MAURO VP, EDELMAN GM: Identification of two short internal ribosome entry sites selected from libraries of random oligonucleotides. Proc. Natl. Acad. Sci. USA (2001) 98:1471-1476.
78. DOUIN-ECHINARD V, PERON JM, LAUWERS-CANCES V, FAVRE G, COUDERC B: Involvement of CD70 and CD80 intracytoplasmic domains in the co-stimulatory signal required to provide an antitumor immune response. Int. Immunol. (2003) 15:359-372.
79. LAUFS S, KIM SH, KIM S, BLAU N, THONY B: Reconstitution of a metabolic pathway with triple-cistronic IRES-containing retroviral vectors for correction of tetrahydrobiopterin deficiency. J. Gene Med. (2000) 2:22-31.
80. WEN XY, MANDELBAUM S, LI ZH et al.: Tricistronic viral vectors coexpressing interleukin-12 (IL-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma. Cancer Gene Ther. (2001) 8:361-370.
81. FAN L, OWEN JS, DICKSON G: Construction and characterization of polycistronic retrovirus vectors for sustained and high-level coexpression of apolipoprotein A-I and lecithin-cholesterol acyltransferase. Atherosclerosis (1999) 147:139-145.
82. QIAN SB, LI Y, QIAN GX, CHEN SS: Efficient tumor regression induced by genetically engineered tumor cells secreting interleukin-2 and membrane-expressing allogeneic MHC class I antigen. J. Cancer Res. Clin. Oncol. (2001) 127:27-33.
83. WANG S, BEATTIE GM, HAYEK A, LEVINE F: Development of a VSV-G protein pseudotyped retroviral vector system expressing dominant oncogenes from a lacO-modified inducible LTR promoter. Gene (1996) 182:145-150.
84. DE FELIPE P: Skipping the coexpression problem: the new 2A 'CHYSEL' technology. Genet. Vaccines Ther. (2004) 2:13.
85. RYAN MD, KING AM, THOMAS GP: Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J. Gen. Virol. (1991) 72:2727-2732. An analysis of the amino acid residues required for FMDV 2A peptide-mediated 'cleavage' of proteins.
86. RYAN MD, DREW J: Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. EMBO J. (1994) 13:928-933.
87. DONNELLY ML, HUGHES LE, LUKE G et al.: The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J. Gen. Virol. (2001) 82:1027-1041.
88. DONNELLY ML, LUKE G, MEHROTRA A et al.: Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J. Gen. Virol. (2001) 82:1013-1025.
89. DEFELIPER RYAN MD: Targeting of proteins derived from self-processing polyproteins containing multiple signal sequences. Traffic (2004) 5:616-626.
90. KLUMP H, SCHIEDLMEIER B, VOGT B, RYAN M, OSTERTAG W, BAUM C: Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategy. Gene Ther. (2001) 8:811-817.
91. FURLER S, PATERNA JC, WEIBEL M, BUELER H: Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons. Gene Ther. (2001) 8:864-873.
92. DE FELIPE P, IZQUIERDO M: Tricistronic and tetracistronic retroviral vectors for gene transfer. Hum. Gene Ther. (2000) 11:1921-1931.
93. DE FELIPE P, HUGHES LE, RYAN MD, BROW JD: Co-translational, incraribosomal cleavage of polypeptides by the foot-and-mouth disease virus 2A peptide. J. Biol. Chem. (2003) 278:11441-11448.
94. PERCY N, BARCLAY WS, GARCIA-SASTRE A, PALESE P: Expression of a foreign protein by influenza A virus. J. Virol. (1994) 68:4486-4492.
95. LORENS JB, PEARSALL DM, SWIFT SE et al.: Stable, stoichiometric delivery of diverse protein functions. J. Biochem. Biophys. Methods (2004) 58:101-110.
96. SZYMCZAK AL, WORKMAN CJ, WANG Y et al.: Addendum: Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat. Biotechnol. (2004) 22:760.
97. DE FELIPE P, MARTIN V, CORTES ML, RYAN M, IZQUIERDO M: Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy. Gene Ther. (1999) 6:198-208.
98. DE FELIPE P, IZQUIERDO M: Construction and characterization of pentacistromc retrovirus vectors. J. Gen. Virol. (2003) 84:1281-1285.
99. MA C, MITRA A: Intrinsic direct repeats generate consistent post-transcriptional gene silencing in tobacco. Plant J. (2002) 31:37-49.
100. KLAUSNER RD, LIPPINCOTT-SCHWARTZ J, BONIFACINO JS: The T cell antigen receptor: insights into organelle biology. Annu. Rev. Cell Biol. (1990) 6:403-431.
101. ARNOLD PY, LAGRUTA NL, MILLER T et al.: The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues. J. Immunol. (2002) 169:739-749.
102. DONNELLY ML, GANI D, FLINT M, MONAGHAN S, RYAN MD: The cleavage activities of aphthovirus and cardiovirus 2A proteins. J. Gen. Virol. (1997) 78(Pt 1):13-21.